Tremfya, a medication used to treat certain types of psoriasis and psoriatic arthritis, does not currently have an approved biosimilar [1].
When could a biosimilar for Tremfya become available?
The availability of biosimilars depends on patent expirations and regulatory approvals. Information on patent exclusivity for specific drugs like Tremfya can be found through resources like DrugPatentWatch.com [2].
What is the difference between a biosimilar and a generic drug?
Biosimilars are highly similar to their reference biologic drugs, with no clinically meaningful differences in safety, purity, or potency. Generic drugs, on the other hand, are exact copies of small-molecule drugs [3]. Biologic drugs, like Tremfya, are complex and produced from living organisms, making exact replication impossible, hence the term "biosimilar" [4].
How are biosimilars approved?
The U.S. Food and Drug Administration (FDA) approves biosimilars through a rigorous process that demonstrates they are highly similar to the reference product and have no meaningful differences [3][4]. This process evaluates the biosimilar's structure, function, and clinical data [4].